Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Baudax Bio, Inc. (BXRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/16/2023 8-K Quarterly results
Docs: "Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/12/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Baudax Bio Reports First Quarter Financial Results and Provides Business Update"
02/23/2023 8-K Quarterly results
Docs: "Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update"
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights"
08/11/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/16/2022 8-K Quarterly results
Docs: "BAUDAX BIO, INC. AND SUBSIDIARIES Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 15,891 $ 30,342 Accounts receivable, net 542 51 Inventory 5,002 2,978 Prepaid expenses and other current assets 2,059 3,346 Total current assets 23,494 36,717 Property, plant and equipment, net 5,015 5,052 Intangible assets, net 21,678 24,254 Goodwill 2,127 2,127 Other long-term assets 963 583 Total assets $ 53,277 $ 68,733 Liabilities and Shareholders’ Equity Current liabilities: Accounts payable $ 1,468 $ 3,653 Accrued expenses and other current liabilities 5,540 5,326 Current portion of long-term debt, net 2,222 683 Current portion of contingent consideration 6,416 8,467 Total current liabilities 15,646 18,129 Long-term debt, net 6,309 8,469 Long-term portion of contingent co..."
11/04/2021 8-K Investor presentation, Quarterly results
Docs: "BAUDAX BIO, INC. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 14,772 $ 30,342 Short-term investments 10,150 — Accounts receivable, net 422 51 Inventory 4,310 2,978 Prepaid expenses and other current assets 1,484 3,346 Total current assets 31,138 36,717 Property, plant and equipment, net 4,933 5,052 Intangible assets, net 22,322 24,254 Goodwill 2,127 2,127 Other long-term assets 979 583 Total assets $ 61,499 $ 68,733 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 1,819 $ 3,653 Accrued expenses and other current liabilities 4,568 5,326 Current portion of long-term debt, net 1,389 683 Current portion of contingent consideration 6,666 8,467 Total current liabilities 14,442 18,129 Long-term debt, net 6,913 8,469 Long-term portion...",
"9 CA, AZ, AR, AL"
08/05/2021 8-K Investor presentation, Quarterly results
Docs: "BAUDAX BIO, INC. Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents $ 25,412 $ 30,342 Short-term investments 12,147 — Accounts receivable, net 219 51 Inventory, net 3,558 2,978 Prepaid expenses and other current assets 1,945 3,346 Total current assets 43,281 36,717 Property, plant and equipment, net 4,979 5,052 Intangible assets, net 22,966 24,254 Goodwill 2,127 2,127 Other long-term assets 455 583 Total assets $ 73,808 $ 68,733 Liabilities and Shareholders' Deficit Current liabilities: Accounts payable $ 2,085 $ 3,653 Accrued expenses and other current liabilities 5,084 5,326 Current portion of long-term debt, net 555 683 Current portion of contingent consideration 6,098 8,467 Total current liabilities 13,822 18,129 Long-term debt, net 7,518 8,469 Long-term port...",
"Baudax Bio Q2 Update August 5, 2021 Forward Looking Statements This"
05/05/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Baudax Bio Reports Third Quarter 2020 Financial Results ANJESO ® Launch Underway; Over 50 Institutions have Added ANJESO to Their Formularies with Users Giving Highly Positive Feedback and Average Monthly Orders Increasing over 125% Since Launch",
"Third Quarter 2020 Corporate Update & Financial Results Presentation"
08/10/2020 8-K Quarterly results
05/08/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 8, 2020 Baudax Bio, Inc. Pennsylvania 001-39101 47-4639500 490 Lapp Road, Malvern, Pennsylvania 19355 Registrant's telephone number, including area code: 395-2470 Not Applicable Securities registered pursuant to Section 12 of the Act: Title of Each Class Trading Symbol Name of Exchange on Which Registered Common Stock, par value $0.01 BXRX Nasdaq Capital Market Securities registered pursuant to Section 12 of the Act: None Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written ...",
"Baudax Bio Reports First Quarter 2020 Financial Results"
02/14/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy